Virus-fighting startup Singletto closed a $10 million Series A investment round and is now selling its pathogen-killing face masks on Amazon. The Seattle company was also selected by the U.S. Defense ...
Please provide your email address to receive an email when new articles are posted on . The FDA based nerandomilast’s approval on results from two trials, one of which was the FIBRONEER-IPF trial.
The FDA has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis, a rare, progressive lung disease that can cause scarring and breathing difficulties. The approval marks the ...
The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF). This is the first new therapy in more than 10 years to be approved for ...
Share on Pinterest The FDA recently approved a generic abortion pill that’s considered as safe and effective as mifepristone. Shuran Huang for The Washington Post via Getty Images The approval, ...
The updated indications state that if TNF blockers are clinically inadvisable, patients may still be administered Rinvoq if they have previously received at least 1 approved systemic therapy. The Food ...
Novartis has secured FDA approval for its BTK inhibitor remibrutinib (Rhapsido) for the treatment of chronic spontaneous urticaria. Remibrutinib is the sixth BTK inhibitor to market in the US, and the ...
The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment. The FDA has approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of adults with ...
The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday.
Opinion
A sports device to ‘protect the brain’ illustrates a major problem with the FDA de novo pathway
This is not just about one device. It’s about what happens when institutions grow comfortable living in their own ambiguity and hiding behind opacity.” ...
The FDA has adjusted the label of Johnson & Johnson and Legend Biotech’s Carvykti, warning patients and doctors that use of the multiple myeloma treatment could increase the risk of an intestinal ...
Cemiplimab significantly reduces the risk of disease recurrence or death by 68% in high-risk CSCC patients post-surgery and radiation. The phase 3 C-POST trial provided the basis for FDA approval, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback